What is Imagene AI?
Imagene AI specializes in AI-based molecular testing, a transformative approach to cancer diagnostics that utilizes existing histological slides to identify actionable biomarkers. By bypassing the need for additional tissue samples, the company's technology provides rapid, cost-effective, and highly accurate molecular profiling. This innovation is essential for oncologists who require precise data to tailor therapeutic interventions, thereby improving patient outcomes and optimizing treatment efficacy in a clinical setting.
The firm operates at the intersection of computational pathology and molecular biology, creating a scalable infrastructure that integrates seamlessly into hospital workflows. As the demand for personalized medicine grows, Imagene AI's platform serves as a vital tool for healthcare providers seeking to enhance the standard of care through data-driven diagnostics.
How much funding has Imagene AI raised?
Imagene AI has raised a total of $44.5M across 3 funding rounds:
Angel/Seed
$3M
Series A
$18.5M
Series B
$23M
Angel/Seed (2022): $3M with participation from Blumberg Capital Partners
Series A (2022): $18.5M led by Dr. David Agus, Larry Ellison, and Eyal Gura
Series B (2025): $23M supported by Larry Ellison and Aguras Pathology Investments
Key Investors in Imagene AI
Larry Ellison
A prominent technology visionary and investor with a deep interest in the intersection of data science and healthcare innovation.
Aguras Pathology Investments
A specialized investment vehicle focused on advancing diagnostic technologies and pathology-related medical breakthroughs.
Dr. David Agus
A renowned physician and researcher specializing in oncology and the application of innovative technologies to improve patient longevity.
What's next for Imagene AI?
With the successful completion of its latest funding round, Imagene AI is poised to scale its commercial operations and expand its diagnostic reach across global healthcare markets. The strategic focus will likely center on deepening clinical partnerships, enhancing the predictive capabilities of its AI models, and securing regulatory milestones necessary for widespread adoption. As the company matures, it remains well-positioned to influence the future of oncology by standardizing molecular testing through its unique, non-invasive digital approach.
The continued support from high-profile investors suggests a long-term commitment to scaling the company's technological footprint. Future initiatives will likely prioritize the integration of its diagnostic suite into broader electronic health record systems, ensuring that clinicians have real-time access to critical molecular data, ultimately driving the next generation of precision cancer care.
